About Singlera Genomics

Singlera Genomics specializes in liquid biopsy technology for early cancer detection, utilizing methylation detection methods to assess cancer risk and monitor treatment response. The company addresses the challenge of late-stage cancer diagnosis by providing non-invasive genetic testing solutions for various high-incidence cancers.

```xml <problem> Late-stage cancer diagnosis significantly reduces treatment options and survival rates. Traditional cancer screening methods often lack the sensitivity to detect tumors at early, more treatable stages, particularly for high-incidence cancers. The need for invasive biopsies for diagnosis and monitoring also presents risks and discomfort for patients. </problem> <solution> Singlera Genomics develops liquid biopsy tests for early cancer detection and monitoring, utilizing advanced methylation detection technology. Their non-invasive blood tests analyze circulating tumor DNA to identify cancer risk, diagnose tumors at earlier stages, guide medication selection, and monitor recurrence. By detecting cancer signals in blood samples, Singlera Genomics aims to improve patient outcomes through earlier intervention and personalized treatment strategies. Their comprehensive range of products and solutions covers cancer early screening, diagnosis, and prognostic monitoring for a variety of cancers such as lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, pancreatic cancer, and thyroid cancer. </solution> <features> - Methylation detection technology for analyzing circulating tumor DNA in blood samples - Non-invasive liquid biopsy approach, eliminating the need for traditional biopsies - Early cancer detection for improved treatment outcomes - Risk assessment for individuals at high risk of developing cancer - Medication guidance based on tumor genetic profiles - Recurrence monitoring to detect cancer relapse early </features> <target_audience> The primary target audience includes individuals at high risk for cancer, patients undergoing cancer treatment, and healthcare providers seeking advanced diagnostic tools for early cancer detection and personalized medicine. </target_audience> <revenue_model>  </revenue_model> ```

What does Singlera Genomics do?

When was Singlera Genomics founded?

Singlera Genomics was founded in 2013.

How much funding has Singlera Genomics raised?

Singlera Genomics has raised 44900000.

Founded

2013

Funding

44900000

Employees

32 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Singlera Genomics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

singleragenomics.com 700+

Crunchbase

Founded 2013

Funding

Estimated Funding

$20M+

Team (30+)

No team information available.

Company Description

Problem

Late-stage cancer diagnosis significantly reduces treatment options and survival rates. Traditional cancer screening methods often lack the sensitivity to detect tumors at early, more treatable stages, particularly for high-incidence cancers. The need for invasive biopsies for diagnosis and monitoring also presents risks and discomfort for patients.

Solution

Singlera Genomics develops liquid biopsy tests for early cancer detection and monitoring, utilizing advanced methylation detection technology. Their non-invasive blood tests analyze circulating tumor DNA to identify cancer risk, diagnose tumors at earlier stages, guide medication selection, and monitor recurrence. By detecting cancer signals in blood samples, Singlera Genomics aims to improve patient outcomes through earlier intervention and personalized treatment strategies. Their comprehensive range of products and solutions covers cancer early screening, diagnosis, and prognostic monitoring for a variety of cancers such as lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, pancreatic cancer, and thyroid cancer.

Features

Methylation detection technology for analyzing circulating tumor DNA in blood samples

Non-invasive liquid biopsy approach, eliminating the need for traditional biopsies

Early cancer detection for improved treatment outcomes

Risk assessment for individuals at high risk of developing cancer

Medication guidance based on tumor genetic profiles

Recurrence monitoring to detect cancer relapse early

Target Audience

The primary target audience includes individuals at high risk for cancer, patients undergoing cancer treatment, and healthcare providers seeking advanced diagnostic tools for early cancer detection and personalized medicine.

Revenue Model